Andre Henri Goy, MD, discusses key developments in mantle cell lymphoma presented at the 2025 ASH Annual Meeting.
Andre H. Goy, MD, MS
Advertisement
Articles by Andre H. Goy, MD, MS
Andre H. Goy, MD, discusses the potential utility of BTK inhibitors as maintenance therapy in mantle cell lymphoma.
Andre H. Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses the utility of novel agents in mantle cell lymphoma (MCL).
Andre H. Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses preliminary data with the combination of ibrutinib (Imbruvica) and venetoclax (Venclexta) in relapsed/refractory mantle cell lymphoma (MCL).
Advertisement
Latest Updated Articles
Dr Goy on the Expanding Role of Combinations and CAR T-Cell Therapy in High-Risk Mantle Cell LymphomaPublished: December 22nd 2025 | Updated:
Dr. Goy on Preliminary Data With Ibrutinib/Venetoclax in Relapsed/Refractory MCLPublished: January 14th 2020 | Updated:
Dr. Goy on the Utility of Novel Agents in MCLPublished: February 4th 2020 | Updated:
Dr. Goy on the Potential Utility of BTK Inhibitors as Maintenance in MCLPublished: May 10th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
NP-G1-044 Receives FDA Orphan Drug Designation for Pancreatic Cancer
3
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
4
Ixazomib-Based Regimens Expand Options in Relapsed/Refractory Multiple Myeloma
5